Browsing Tag
dermatology biologics
2 posts
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
Sanofi bets on dosing discipline over rapid onset with amlitelimab’s Phase 3 readout
Sanofi moves amlitelimab toward global filings. Find out what the Phase 3 data mean for investors, competitors, and the dermatology biologics market.